Top Headlines

Breaking News

CRL abandons Wuxi takeover after shareholder opposition

Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.

Related news

News in brief

Covance op income down as Phase III delays hit margins

Covance has recorded a 29 per cent drop in operating income, despite revenue growth, as cost reduction actions and Phase III delays hit margins.

Chiltern grows market share in FY 2010; plans global expansion

CRO Chiltern International says market share grew in fiscal 2010, citing strengthened industrial relationships and global expansion as drivers.

Exclusive interview

Demand for discovery services recovering, says Domainex

Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.

Guest article

Pharma consolidation and the downstream impact on CROs

Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).

Icon op income down; “pretty active” in pursuit of M&A

Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future.

Today's headlines across the Pharmaceutical industry

Solid diabetes sales drive slight Q3 growth at BD Medical from in-PharmaTechnologist.com

The medical unit of Becton Dickinson (BD) reported a slight increase in revenues in the third quarter driven by solid sales of diabetes products.

Marina buys Smarticles liposomal delivery system from in-PharmaTechnologist.com

Marina Biotech has acquired the intellectual property for the Smarticles liposomal-based delivery system from Novosom AG.

News in brief

Hovione grows sales in 09 from in-PharmaTechnologist.com

Consolidated sales at Hovione increased by 15 per cent to $144m (€110m) in fiscal 2009.

On your radar